Blab Business
Prasol Chemicals Launches 500-Crore IPO, Aims to Reduce Debt and Expand Specialty Chemical Reach
Prasol Chemicals Ltd. is set to open its initial public offering on September 8, 2026, with a price band of ₹643 to ₹676 per share. The filing will close on September 10, and anchor‑investor bidding is slated for September 7. The ₹500‑crore issue will comprise a fresh equity issuance of up to ₹80 crore and an offer‑for‑sale of up to ₹420 crore by existing shareholders.
At the upper end of the band, Prasol would be valued at roughly ₹6,001 crore. The fresh portion of the offering is earmarked for debt repayment, working‑capital needs, and general corporate purposes. The company, originally Prachi Poly Products Private Ltd., adopted the Prasol Chemicals name in 2007 and returned to public markets in 2022.
Prasol is a forward‑integrated producer of acetone and phosphorus‑based specialty chemicals, as well as other differentiated products. Its acetone and phosphorus derivatives find use in pharmaceuticals, agrochemical synthesis, and formulations, while its broader specialty‑chemical portfolio supplies raw materials for sunscreens, shampoos, fragrances, and disinfectants. The firm is also the sole Indian manufacturer of isophorone, a solvent and polymer precursor.
SBI Securities, one of the book‑running lead managers, recommends the IPO to long‑term investors. The brokerage cites a diversified product mix and the company’s unique position as India’s only isophorone producer. It notes that revenue, EBITDA, and adjusted PAT grew at 18.6 %, 51.7 %, and 97.8 % respectively over FY24‑FY26. Prasol expects ₹60 crore of the fresh issue to repay borrowings, lowering the debt‑to‑equity ratio to 0.1x from 0.2x in FY26. At ₹676, the issue’s price‑to‑earnings ratio is 48.1x based on post‑issue capital, a figure the brokerage deems reasonable compared with peers.
Anand Rathi of SBI Securities highlights the company’s diversified customer base and expanding global presence, which enhance revenue visibility. He points out that the specialty‑chemical business benefits from high entry barriers, including lengthy 1–4‑year customer approval cycles, complex chemistry, high product‑development costs, and stringent regulatory requirements. These factors create customer stickiness and make supplier displacement difficult, supporting long‑term revenue visibility.
The brokerage also notes operational risks tied to manufacturing facilities, where unplanned shutdowns could disrupt activity. It assigns a “subscribe for long term” rating to the issue.
Prasol’s IPO will be listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) with a tentative listing date of September 16, 2026. The lot size for applications is 22 shares.
The company’s product mix places it in several high‑growth segments. Acetone is a key solvent in the chemical industry, while isophorone is used as a solvent and polymer precursor. The firm’s specialty chemicals also support the personal‑care, agrochemical, and pharmaceutical sectors, which are expanding in India and abroad.
The fresh issue will allow Prasol to reduce leverage and invest in capacity expansion. The offer‑for‑sale component gives existing shareholders an exit opportunity while keeping the company’s ownership structure largely unchanged.
Investors will be able to apply through ASBA (Application Supported by Blocked Amount) via banks or brokers. The IPO’s price‑band and lot size are typical for specialty‑chemical firms of similar size. Market participants will monitor the allotment outcome, the company’s debt‑reduction progress, and the performance of its key product lines.
In summary, Prasol Chemicals’ ₹500‑crore IPO opens on September 8, 2026, with a price band of ₹643–₹676. The fresh issue of ₹80 crore will fund debt repayment and working capital, while the offer‑for‑sale of ₹420 crore provides liquidity for existing shareholders. The company’s diversified specialty‑chemical portfolio, unique production capabilities, and planned debt reduction underpin the brokerage’s long‑term subscription recommendation. The listing is slated for September 16, 2026, and the IPO will be available on both NSE and BSE.
At the upper end of the band, Prasol would be valued at roughly ₹6,001 crore. The fresh portion of the offering is earmarked for debt repayment, working‑capital needs, and general corporate purposes. The company, originally Prachi Poly Products Private Ltd., adopted the Prasol Chemicals name in 2007 and returned to public markets in 2022.
Prasol is a forward‑integrated producer of acetone and phosphorus‑based specialty chemicals, as well as other differentiated products. Its acetone and phosphorus derivatives find use in pharmaceuticals, agrochemical synthesis, and formulations, while its broader specialty‑chemical portfolio supplies raw materials for sunscreens, shampoos, fragrances, and disinfectants. The firm is also the sole Indian manufacturer of isophorone, a solvent and polymer precursor.
SBI Securities, one of the book‑running lead managers, recommends the IPO to long‑term investors. The brokerage cites a diversified product mix and the company’s unique position as India’s only isophorone producer. It notes that revenue, EBITDA, and adjusted PAT grew at 18.6 %, 51.7 %, and 97.8 % respectively over FY24‑FY26. Prasol expects ₹60 crore of the fresh issue to repay borrowings, lowering the debt‑to‑equity ratio to 0.1x from 0.2x in FY26. At ₹676, the issue’s price‑to‑earnings ratio is 48.1x based on post‑issue capital, a figure the brokerage deems reasonable compared with peers.
Anand Rathi of SBI Securities highlights the company’s diversified customer base and expanding global presence, which enhance revenue visibility. He points out that the specialty‑chemical business benefits from high entry barriers, including lengthy 1–4‑year customer approval cycles, complex chemistry, high product‑development costs, and stringent regulatory requirements. These factors create customer stickiness and make supplier displacement difficult, supporting long‑term revenue visibility.
The brokerage also notes operational risks tied to manufacturing facilities, where unplanned shutdowns could disrupt activity. It assigns a “subscribe for long term” rating to the issue.
Prasol’s IPO will be listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) with a tentative listing date of September 16, 2026. The lot size for applications is 22 shares.
The company’s product mix places it in several high‑growth segments. Acetone is a key solvent in the chemical industry, while isophorone is used as a solvent and polymer precursor. The firm’s specialty chemicals also support the personal‑care, agrochemical, and pharmaceutical sectors, which are expanding in India and abroad.
The fresh issue will allow Prasol to reduce leverage and invest in capacity expansion. The offer‑for‑sale component gives existing shareholders an exit opportunity while keeping the company’s ownership structure largely unchanged.
Investors will be able to apply through ASBA (Application Supported by Blocked Amount) via banks or brokers. The IPO’s price‑band and lot size are typical for specialty‑chemical firms of similar size. Market participants will monitor the allotment outcome, the company’s debt‑reduction progress, and the performance of its key product lines.
In summary, Prasol Chemicals’ ₹500‑crore IPO opens on September 8, 2026, with a price band of ₹643–₹676. The fresh issue of ₹80 crore will fund debt repayment and working capital, while the offer‑for‑sale of ₹420 crore provides liquidity for existing shareholders. The company’s diversified specialty‑chemical portfolio, unique production capabilities, and planned debt reduction underpin the brokerage’s long‑term subscription recommendation. The listing is slated for September 16, 2026, and the IPO will be available on both NSE and BSE.
